ARSYNL Rx review
One of these figures has already moved once, which makes either worth confirming on the day.
The verdict
Arsynl Rx publishes $219 a month for compounded semaglutide and $269 for tirzepatide, and neither figure has held steady long enough to budget from without checking it first.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- From
- From $219/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Arsynl Rx sells both molecules by injection, each with its own published monthly figure, and the fifty-dollar step between them is the ordinary shape of this market rather than anything unusual to this seller.
Who writes the prescription, and what do they see?
A prescription precedes shipping, and the pages set out rates rather than describing the clinician behind them, so a reader learns what a month costs long before learning anything about who decides that a month is appropriate.
Remote, and organized around the two product lines rather than around a course of care, with nothing published about what a clinician looks at between the first order and the fourth.
What happens when the dose goes up?
Consider the four months most buyers actually spend escalating. Nothing Arsynl Rx publishes says whether $219 is the figure at 0.25 milligrams or at 1.0, nor what it becomes at either end. A reader planning a winter of dose increases is planning against a number with no stated dose attached to it.
What the price includes
Six months of semaglutide at $219 is $1,314 and the tirzepatide line runs to $1,614 over the same span, and both totals hold only for a buyer whose dose stays where it started. More useful than either total: this is a price that has already moved once, so confirm it on the seller's own page on the day you order, including against this one.
What it claims, and what it cites
Both lines are compounded rather than manufactured, prepared by a pharmacy that is not named on any page here, and not reviewed by the FDA before dispensing in the way an approved product is.
Where it holds up, and where it does not
- Strength: Both molecules carry a published figure
- Strength: The tirzepatide premium is modest
- Limitation: No milligram dose stated beside either
- Limitation: Nothing published about dose pricing
- Limitation: No state coverage list recorded
- Limitation: No compounding pharmacy is named
What the evidence says about this kind of treatment
The assessment above is about ARSYNL Rx. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants both molecules priced on one page and will confirm the figure on the day.
- Wrong for
- A reader who needs the dose behind a figure before treating it as comparable.
The evidence behind what ARSYNL Rx prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How ARSYNL Rx compares
| Seller | Who it suits | Go |
|---|---|---|
| Candor Rx | Readers who value a bill that does not move with the dose and will confirm the figure first | See Candor Rx → |
 AquaVita NextGen | Readers who re-check a price on the day of ordering and will benefit from the lower one | See AquaVita NextGen → |
 Clume Health | Readers who want both molecules at one rate and will re-check the figure before paying | See Clume Health → |
More GLP-1 telehealth sellers reviews: GetRelief RxGimme CareGlam HealthGo Vida PlenaGobyMedsGoldspan Health
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- What do the two lines cost?
- Semaglutide is $219 a month and tirzepatide is $269.
- Does either figure hold at a higher dose?
- Arsynl Rx publishes nothing on that question, and an absence of a statement is not a promise that the figure holds, nor evidence that it climbs.
- Will this price hold?
- It has already moved once, so there is no reason to assume it will. Confirm either figure on the seller's own page before the first charge.
- Is ARSYNL Rx expensive compared with other GLP-1 telehealth sellers?
- ARSYNL Rx publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ARSYNL Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.